<DOC>
	<DOCNO>NCT02989922</DOCNO>
	<brief_summary>This randomize controlled Phase 2/3 study evaluate efficacy safety SHR-1210 subject advance HCC fail intolerable prior systemic treatment . The primary study hypothesis SHR-1210 treatment improve Objective Response Rate Overall Survival compare SOC .</brief_summary>
	<brief_title>A Study Evaluate SHR-1210 Subjects With Advanced HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Histologically confirm HCC advance stage ; suitable surgery local regional treatment ; least one measurable lesion per RECIST 1.1 2 . Failed intolerable least one prior systemic treatment advance HCC 3 . ECOG Performance Status 0 or1 4 . ChildPugh Class A B 7 point 5 . Life Expectancy least 12 week 6 . HBV DNAï¼œ2000 IU/ml 7 . Adequate organ function 8 . Male female participant childbearing potential must willing use adequate method contraception start first dose study drug 60 day female subject 120 day male subject last dose study drug 1 . Known fibrolamellar HCC , sarcomatoid HCC , mixed cholangiocarcinoma HCC 2 . Known liver transplant plan transplant 3 . GI hemorrhage 6 month 4 . Symptomatic brain metastasis 5 . Active know , suspect autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>